Vivo Capital
VC Fund
Palo Alto, United States
Vivo Capital is a VC fund in Palo Alto focused on Biotechnology and Health Care. The firm is a 25-year-old global investment firm focused on healthcare with approximately $5.8 billion in AUM, which we have invested in over 290 public and private companies worldwide. Headquartered in Palo Alto, California, with offices in Asia. Our team consists of 50 multi-disciplinary professionals, including, physicians, scientists,entrepreneurs, operating executives, and industry experts. The firm operates as a multi-fund investment platform, covering growth equity, private equity including buyout, venture capital, and public equity. Vivo invests broadly in healthcare across all fund strategies, including biotechnology, pharmaceuticals, medical devices, and healthcare services, with a focus on the largest healthcare markets.
- Total investments:
- 265
- Last investment:
- Lead investor:
- 27%
- Fund size:
- $740M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Vivo Capital invests in
Stages Vivo Capital invests in
Countries Vivo Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 12 contacts → | |||
Round size
- Series B
- $28M–$137M
- Series C
- $30M–$142M
- Post-IPO Equity
- $35M–$180M
Investment Focus
Industry
- Biotechnology 148 (56%)
- Health Care 110 (42%)
- Pharmaceutical 70 (26%)
- Medical 65 (25%)
- Therapeutics 64 (24%)
Stage
- Post-IPO Equity 60 (23%)
- Series B 45 (17%)
- Series C 38 (14%)
- Series A 37 (14%)
- Series D 17 (6%)
Country
- United States 135 (51%)
- China 24 (9%)
- United Kingdom 6 (2%)
- Canada 4 (2%)
- France 2 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Gaurav Aggarwal
Managing Director
|
Managing Director | Total investments: 6 | Find email | |
Michael Chang
Managing Partner
|
Managing Partner | Total investments: 0 | Find email | |
Shan Fu
Managing Partner, Co-CEO, and CEO of Asia Pacific
|
Managing Partner, Co-CEO, and CEO of Asia Pacific | Total investments: 6 | Find email | |
Chloe Zhang
Principal
|
Principal | Total investments: 0 | Find email | |
Edgar G. Engleman
Co - Founder & Managing Partner
|
Co - Founder & Managing Partner | Total investments: 5 | Find email | |
| See all 12 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Serán is a contract development and manufacturing organization providing a comprehensive suite of development, analytical and clinical manufacturing services to pharmaceutical and biotechnology companies. | Private Equity / Sep 29, 2026 | ||
| Korsana Biosciences develops THETA-enabled antibody therapies for neurodegenerative diseases. The company focuses on shuttled monoclonal antibodies that cross the blood-brain barrier to reach central nervous system targets. Its lead program, KRSA-028, is an investigational anti-amyloid beta antibody for Alzheimer’s disease that uses a transferrinreceptor-based shuttle and Fc engineering to improve brain delivery and dosing. Korsana is also advancing additional THETA-based programs for undisclosed neurodegenerative indications. | $380M / Post-IPO Equity / Sep 08, 2026 | ||
| Expedition Therapeutics operates as an unincorporated association. | $115M / Series B / Aug 05, 2026 | ||
| Entera Bio is developing novel oral drugs by utilizing its proprietary cutting edge delivery technology This technology protects large molecules and peptides in the GI tract. Oral drug delivery is the most straight forward and user friendly approach to medical treatment. Entera Bio has key personnel with the relevant know how, experience andnetworks working together to enable rapid development of its products. The company has an experienced management team with more than 50 years of combined drug development experience. | $275M / Post-IPO Equity / Jul 27, 2026 | ||
| Mentari Therapeutics is a biotechnology company developing therapies for the prevention of migraine. | $200M / Private Equity / Jul 22, 2026 | ||
| SonoThera is a biotechnology company that creates non-viral genetic therapies using ultrasound. Its mission is to develop genetic medicines that treat the root cause of human disease. SonoThera is expanding the possibilities of disease treatment with ultrasound-guided nonviral gene therapy for diseases with suboptimal or non-existent treatments. Itaims to improve the lives and health of millions of people. | $125M / Series B / Jun 10, 2026 | ||
| Full-Life Technologies Limited (“Full-Life”) is a fully integrated global RadioTherapeutics company headquartered in Shanghai, China with operations in Europe. | $109M / Series D / May 18, 2026 | ||
| Immunocan focuses on the development of fully human antibody animals, artificial chromosome carriers with independent intellectual property rights, focusing on tumor treatment, and developing antibody therapeutic drugs. | $36.8M / Series A / May 13, 2026 | ||
| Valneva is a pharmaceutical company developing prophylactic vaccines to treat infectious diseases. The company focused on developing and commercializing prophylactic vaccines for infectious diseases with significant unmet medical needs. Valneva has leveraged its expertise and capabilities both to commercialize two vaccines successfully and torapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus, and COVID-19. | $43.1M / Post-IPO Equity / Apr 30, 2026 | ||
| Achieve Life Science manufactures pharmaceutical products. The firm develops cytisine as a smoking cessation aid. | $180M / Post-IPO Equity / Apr 16, 2026 | ||
| See all 265 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Vivo Capital invest in?
Vivo Capital invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Post-IPO Equity and Series B stage. Most of the 265 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Vivo Capital's check size?
Vivo Capital typically joins rounds of $28M–$137M at Series B, $30M–$142M at Series C and $35M–$180M at Post-IPO Equity. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Vivo Capital participates in.
How do I contact Vivo Capital?
Public channels for Vivo Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Vivo Capital?
The team at Vivo Capital includes Gaurav Aggarwal (Managing Director), Michael Chang (Managing Partner) and Shan Fu (Managing Partner, Co-CEO, and CEO of Asia Pacific), among 12 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
